Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed an 8-K current report with the SEC on May 26, 2026 reporting Item 8.01 (Other Events), Item 7.01 (Regulation FD Disclosure). New clinical trial collaboration and supply agreement with Bayer Consumer Care AG.
Olema Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- New clinical trial collaboration and supply agreement with Bayer Consumer Care AG
- Partnership may support Olema’s clinical development through Bayer-provided supply and collaboration
- Press release dated May 26, 2026 contains the substantive agreement details
- Exhibit 99.1 furnished under Regulation FD, not treated as filed under Section 18 liability rules
Item 8.01 · Other Events
- Olema–Bayer Phase 1b/2 trial evaluating OP-3136 plus NUBEQA in approximately 36 patients with mCRPC
- Trial initiation expected in the second half of 2026, adding a clinical catalyst for OP-3136
- Bayer supplying darolutamide while Olema leads study execution, reducing collaboration-related drug supply burden
- Olema retains full global commercial and marketing rights to OP-3136
- First clinical collaboration for OP-3136, with combination data and inventions jointly owned
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Olema Pharmaceuticals, Inc. 8-K filings
Get the next OLMA 8-K as it lands
Follow OLMA for push alerts, or ask the research agent what this filing means.